Brainsway Receives New Buy Rating: 20‑30% Upside on TMS Growth
Brainsway’s fresh buy rating from BTIG and H.C. Wainwright highlights strong TMS growth and a 20‑30 % upside for investors in neuromodulation.
2 minutes to read
BRAINSWAY LTD
Brainsway Gains Investor Confidence With Analyst Bullish Outlook & Sound Minds Strategic Stake
Brainsway’s bullish outlook grows stronger as H.C. Wainwright reaffirms a $14 target and Buy rating, while its stake in Sound Minds Behavioral expands its behavioral‑health reach.
2 minutes to read
Brainsway Ltd. Bolsters Neuromodulation Market with Strategic Investments in Neurolief and Mental Health Services
Brainsway Ltd. has made strategic investments in Neurolief and Axis to expand its influence in the neuromodulation market and enhance its offerings for treating mental health disorders.
2 minutes to read
Brainsway Ltd. Leads the Charge in Non-Invasive Neuromodulation for Mental Health
Brainsway Ltd. is a pioneering company in non-invasive neuromodulation, specializing in treatments for major depressive disorder and obsessive-compulsive disorder, with a strong market presence and growth potential.
2 minutes to read